Noom Pricing Analysis & Total Cost: Is It Worth It for Women?

What Does Noom Actually Cost? The Real Monthly Number

The advertised price and the all-in cost are two different figures. Noom's core app subscription runs about $70 per month if you pay month-to-month, or closer to $17 to $20 per month if you commit to an annual plan priced around $199 per year. The annual plan requires full prepayment, so your upfront charge is nearly $200 before you have confirmed the program works for you.

If you add Noom Med, the company's telehealth prescribing layer, costs climb quickly.

The App-Only Tier

The baseline Noom program includes daily lessons built on cognitive behavioral therapy concepts, food logging with a color-coded traffic-light system, and access to a "Goal Specialist," who is an asynchronous text-based coach. The coach is not a registered dietitian, a licensed therapist, or a nurse practitioner. Noom's own terms clarify that Goal Specialists are trained by Noom but do not hold clinical licenses.

For women whose primary need is behavioral structure and accountability, this tier may be adequate. For women managing PCOS-related insulin resistance, perimenopause-driven metabolic changes, or postpartum weight retention, a non-clinical coach has real limits.

Noom Med: GLP-1 and Medication Costs

Noom Med is a separate telehealth service layered on top of the app. A prescriber evaluates you via asynchronous questionnaire, and if eligible, you may receive a prescription for semaglutide (oral or injectable), metformin, or other agents. Pricing for the medication component ranges roughly $149 to $349 or more per month depending on the drug, dose, and fulfillment pharmacy, based on publicly available Noom Med pricing pages as of early 2025.

That puts the realistic all-in monthly cost at $170 to $420 for the combination of app plus medication. Insurance rarely covers the medication portion when obtained through a direct-to-consumer telehealth company rather than a traditional prescriber.

Hidden Costs to Anticipate

• Lab work is not included and is required before GLP-1 initiation. Expect $50 to $150 out of pocket if uninsured.
• Dose escalations may cost more as you move to higher weekly injectable doses.
• Canceling the annual plan mid-year typically yields no refund.
• If you stop the app but keep Noom Med, you still pay the app fee for the remainder of your billing cycle.

Is the Clinical Evidence Behind Noom's Approach Sound?

Noom's behavioral model draws on cognitive behavioral therapy and self-monitoring, both of which have genuine evidence in weight management. The LOOK AHEAD trial demonstrated that intensive lifestyle intervention (including behavioral strategies) produced meaningful weight loss and cardiovascular risk reduction in adults with type 2 diabetes over four years. That is not a Noom trial, and Noom's own published data deserves scrutiny.

What Noom's Own Research Shows

Noom published a retrospective analysis of 36,000 users in Scientific Reports in 2019 reporting that 77.9 percent of users lost weight over the program period. The study was funded by Noom, used self-reported data, and lacked a control group. Dropout was significant, and the analysis excluded users who did not complete the program, a classic completer-only bias that inflates success rates.

A separate 2023 randomized controlled trial published in Obesity compared Noom to a standard care control over 52 weeks. Noom participants lost a mean of 4.1 percent of body weight versus 1.3 percent in the control group. That difference is statistically significant but modest. For context, GLP-1 receptor agonists in dedicated trials routinely produce 10 to 15 percent body weight reduction.

The GLP-1 Evidence Is Stronger Than the App Evidence

The phase 3 STEP 1 trial of once-weekly subcutaneous semaglutide 2.4 mg in adults with obesity found a mean weight reduction of 14.9 percent at 68 weeks versus 2.4 percent with placebo. Women made up 74.1 percent of the STEP 1 trial population, making this one of the better-represented female datasets in obesity pharmacotherapy. If GLP-1 medication is clinically appropriate for you, the medication is doing most of the weight-loss work, and the question becomes whether Noom's app layer is the best delivery vehicle for it.

Women's Physiology: Why Generic Weight Programs Often Miss the Mark

Weight regulation in women is not the same as in men. Estrogen influences adipose tissue distribution, leptin sensitivity, and energy intake across the menstrual cycle. Research published in Physiology & Behavior shows that resting metabolic rate varies by roughly 100 to 150 kcal per day across menstrual phases, with lower energy expenditure in the follicular phase and a modest rise post-ovulation. A calorie-tracking app that treats every day identically misses this biology entirely.

Noom's color-coded food system does not adjust for menstrual cycle phase, hormonal contraceptive use, pregnancy status, or menopause-related shifts in body composition. This is a structural gap, not a minor quibble.

Reproductive Years and PCOS

Women with PCOS carry a prevalence of insulin resistance estimated at 65 to 70 percent, even among those who are not overweight. Behavioral weight loss and caloric restriction can reduce androgen levels and restore ovulatory function, but the magnitude of benefit depends on the degree of insulin resistance, not just caloric deficit. Metformin, available through Noom Med, has an established evidence base in PCOS per ACOG Practice Bulletin No. 194, though it is not FDA-approved specifically for PCOS and functions off-label in this context.

GLP-1 receptor agonists in PCOS have shown promise in small trials. A 2022 meta-analysis in Fertility and Sterility found that GLP-1 agonists reduced BMI, fasting insulin, and free androgen index in women with PCOS, though the trials were short and heterogeneous. Noom does not market itself specifically to PCOS populations, and its coaching staff would not be positioned to manage the condition's reproductive consequences.

Perimenopause and Postmenopause

The menopause transition brings a shift toward central adiposity even when total body weight is stable, driven by declining estrogen rather than excess calories alone. A 2023 paper in Menopause noted that standard behavioral programs produce smaller weight losses in postmenopausal women than in premenopausal women, partly because energy expenditure declines and appetite-regulating hormones shift. Adding GLP-1 therapy to behavioral intervention may close some of that gap, but data specific to menopausal women on combined app-plus-GLP-1 programs is thin.

Menopausal hormone therapy (MHT) itself modestly attenuates visceral fat accumulation and may improve metabolic markers, per The Menopause Society's 2022 position statement. If you are perimenopausal and your weight gain is driven primarily by hormonal change rather than behavioral excess, addressing the hormone picture may yield more than a behavioral app.

Postpartum Women

Postpartum weight retention is a distinct clinical situation. GLP-1 receptor agonists are not studied in lactating women, transfer into breast milk is not established, and the FDA label for semaglutide does not include lactation data. Noom Med should not be initiating GLP-1 prescriptions in breastfeeding women, though the responsibility for that screen sits with the prescribing clinician in the telehealth encounter.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting Noom Med

This section is required for any drug-involving program, and the information below applies regardless of which telehealth platform you use.

GLP-1 Receptor Agonists in Pregnancy

Semaglutide is contraindicated in pregnancy. Animal data from reproductive toxicity studies showed fetal harm at doses below clinical human exposure. The FDA label for Ozempic (semaglutide injection) and Wegovy carries a warning to discontinue at least two months before a planned pregnancy. The FDA prescribing information for Wegovy explicitly states: "Discontinue WEGOVY at least 2 months before a planned pregnancy because of the long half-life of semaglutide."

Human data in pregnancy is extremely limited. The GLP-1 agonist class as a whole lacks adequate human gestational safety data, and extrapolation from animal studies suggests a caution posture is appropriate.

Any woman of reproductive potential starting GLP-1 therapy through Noom Med or any other platform should use reliable contraception throughout treatment and for at least two months after the last dose.

Lactation

No published human pharmacokinetic data establishes whether semaglutide transfers meaningfully into breast milk. Given the molecular weight and protein-binding characteristics of the drug, transfer is theoretically possible but may be low. Because the safety profile in infants is unknown, most clinical authorities recommend avoiding GLP-1 agonists during breastfeeding. Noom Med's prescribing process should screen for lactation status; if you are breastfeeding, confirm that this is flagged before any prescription is issued.

Metformin in Pregnancy and Lactation

Metformin has a different profile. It crosses the placenta and has been used off-label in gestational diabetes management. A 2019 Cochrane review found metformin comparable to insulin for glycemic control in gestational diabetes with lower rates of maternal hypoglycemia, though neonatal outcomes require ongoing follow-up. In lactation, metformin transfers into breast milk at low levels and is generally considered compatible with breastfeeding by most authorities, including LactMed. This is a meaningful distinction from the GLP-1 class.

Noom vs. Alternatives: An Honest Comparison

Noom is not the only behavioral weight program, and it is not the only telehealth GLP-1 prescriber. Women researching this decision deserve a side-by-side view.

Behavioral App Alternatives

WeightWatchers (WW) uses a points-based system with optional in-person meetings or virtual coaching. Its evidence base includes a 2011 Lancet trial showing WW produced roughly twice the weight loss of standard GP care at 12 months (5.06 kg vs. 2.25 kg). WW has also integrated GLP-1 prescribing through a separate program tier.

Calibrate was positioned explicitly as a GLP-1 plus metabolic coaching program for women, though the company significantly restructured in 2023. Its model was more clinically intensive than Noom's, with physician oversight rather than non-clinical coaching.

MyFitnessPal is purely a self-directed food and exercise tracker with no coaching or prescribing. Cost is $20 per month for premium features or free with limitations.

Women's Health-Specific Platforms

Several telehealth platforms specialize in women's hormonal health and may better address PCOS, perimenopause, or postpartum weight concerns alongside behavioral tools. These include Midi Health (menopause-focused), Allara (PCOS-focused), and WomanRx's own clinical pathways. None of these is perfect, and cost comparisons should factor in whether clinical oversight is included in the base fee rather than added as a separate line item.

The Independent Prescriber Route

If your primary interest is GLP-1 medication, working with a board-certified obesity medicine physician or your OB-GYN may cost less per month when insurance coverage is factored in. ACOG Committee Opinion 783 notes that anti-obesity medications are underutilized in women's health settings and encourages OB-GYNs to integrate weight management into their scope of practice. Your gynecologist may be a better starting point than a direct-to-consumer app if you have concurrent reproductive or hormonal concerns.

Who This Program Is Right For (and Who Should Look Elsewhere)

May Be a Reasonable Fit If You:

• Are in your reproductive years with no current pregnancy plans and no active hormonal disorder
• Want structured behavioral scaffolding and find app-based daily lessons helpful for accountability
• Have a BMI of 27 or above with a weight-related comorbidity (qualifying for GLP-1 consideration under standard criteria) and do not have access to a local obesity medicine provider
• Are not breastfeeding and are using reliable contraception

Look Elsewhere If You:

• Are pregnant, planning pregnancy within two months, or currently breastfeeding (GLP-1 tier specifically)
• Have active PCOS with fertility goals, where reproductive endocrinology or an OB-GYN familiar with PCOS is a better first stop
• Are in perimenopause or postmenopause and your weight gain is driven primarily by hormonal flux rather than behavioral patterns
• Have a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a contraindication for GLP-1 agonists per FDA labeling
• Need clinical-level nutritional support (e.g., eating disorder history, malabsorption, bariatric post-op), which a non-licensed Goal Specialist cannot provide
• Have pancreatitis history, which requires careful risk-benefit discussion before GLP-1 initiation

The Coaching Quality Gap: What Women Should Expect vs. What Noom Delivers

Noom's Goal Specialists complete a proprietary training program. They are not registered dietitians (RDs), licensed clinical social workers, or psychologists. For the CBT-adjacent content in the app lessons, this may be adequate. For personalized dietary advice around PCOS, gestational weight management, or menopausal metabolic health, it is not.

The Academy of Nutrition and Dietetics defines Medical Nutrition Therapy as a clinical service requiring an RD or RDN credential. Noom's coaching falls outside that definition. If you are comparing Noom's $70 per month for non-clinical coaching against, say, six sessions per year with an RD covered by insurance, the clinical value comparison favors the RD for complex cases.

As WomanRx reviewer Dr. Elena Vasquez, MD, notes: "For a woman managing uncomplicated overweight without hormonal comorbidities, a structured behavioral app with GLP-1 access can be a reasonable bridge when in-person obesity medicine is not accessible. The concern is when women with PCOS, perimenopause, or postpartum hormonal disruption use a non-clinical coaching layer as a substitute for proper evaluation. The app cannot tell you whether your weight gain is insulin-driven, estrogen-driven, or thyroid-driven. That distinction changes the entire treatment approach."

Cancellation, Auto-Renewal, and Consumer Protections

Noom has faced Federal Trade Commission scrutiny. In 2023, the FTC reached a $62 million settlement with Noom over charges that included unauthorized charges and failure to provide an easy cancellation mechanism. The settlement required Noom to change its cancellation practices and issue refunds to affected consumers.

Practical steps to protect yourself:

1. Screenshot your trial end date immediately after signing up.
2. Set a calendar reminder 48 hours before the trial expires.
3. Cancel through the app settings, not just by deleting the app. Deleting the app does not cancel your subscription.
4. For Noom Med, confirm in writing whether canceling the app also cancels the medication subscription or whether these are billed separately.

A Framework for Estimating Your Real First-Year Cost

To give you a concrete working number rather than a range, here is a realistic first-year cost estimate for three common scenarios:

Scenario 1: App only, annual plan. Upfront payment approximately $199. Lab work if pursuing any medical evaluation not through Noom: $0 to $150. Total year one: roughly $199 to $349.

Scenario 2: App plus GLP-1 (semaglutide injectable, starting dose escalating to maintenance). Annual app approximately $199. Noom Med medication tier at roughly $200 to $300 per month average once titrated, multiplied by 12: $2,400 to $3,600. Labs: $100 to $200. Total year one: approximately $2,700 to $4,000.

Scenario 3: Month-to-month app, trying for six months, then canceling. Six months at $70 equals $420. No medication. Total: $420.

The annual app plan is a meaningful discount only if you are confident you will use the program for 10 or more months. At month six, the breakeven point versus the monthly plan is roughly equivalent.